Search Results
Jun 30, 2026, 02:42 ET Sobi to showcase new data across haemophilia portfolio at ISTH 2026
Characteristics of Patients Switching to ProphylacticEfanesoctocog Alfa Therapy Evaluated for Joint Health in HaemophiliaA in Taiwan (PROTECT-ALT Study)In collaboration with Sanofi
More news about: Swedish Orphan Biovitrum AB
Jun 29, 2026, 08:00 ET Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
10% Grade 3/4. 85% of patients experienced increased ALT, including 13% Grade 3/4. Fatal liver events occurred in 0.6% of patients. Median time to first onset of AST or ALT elevation was 15 days (range: 3 days to 20.8 months).Increased AST or ALT each led to dose interruption in 7% of patients and
More news about: Nuvation Bio Inc.
Jun 29, 2026, 03:10 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
enzyme elevation. Hepatic transaminases must be evaluated at baseline and thereafter according to routine patient management. If alanine transaminase (ALT) or aspartate transaminase (AST) increases are observed and drug-induced liver injury is suspected, RINVOQ should be interrupted until this diagnosis
More news about: AbbVie
Jun 29, 2026, 03:10 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
enzyme elevation. Hepatic transaminases must be evaluated at baseline and thereafter according to routine patient management. If alanine transaminase (ALT) or aspartate transaminase (AST) increases are observed and drug-induced liver injury is suspected, RINVOQ should be interrupted until this diagnosis
More news about: AbbVie
Jun 29, 2026, 03:00 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
enzyme elevation. Hepatic transaminases must be evaluated at baseline and thereafter according to routine patient management. If alanine transaminase (ALT) or aspartate transaminase (AST) increases are observed and drug-induced liver injury is suspected, RINVOQ should be interrupted until this diagnosis
More news about: AbbVie
Jun 29, 2026, 03:00 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
enzyme elevation. Hepatic transaminases must be evaluated at baseline and thereafter according to routine patient management. If alanine transaminase (ALT) or aspartate transaminase (AST) increases are observed and drug-induced liver injury is suspected, RINVOQ should be interrupted until this diagnosis
More news about: AbbVie
Jun 26, 2026, 08:43 ET Truss Financial Group Addresses $11 Trillion Untapped Home Equity Problem for Self-Employed Homeowners
momentum. TFG's streamlined automated platform performs a soft credit pull to generate transparent options, matching complex-income applicants with flexible alt-doc guidelines. Instead of navigating weeks of tedious document requests, qualified borrowers receive rapid, predictable funding timelines, completing
More news about: Truss Financial Group
Jun 26, 2026, 07:16 ET Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
AST increased (17; 1.6), pneumonia (16; 14), bruising (16; -), potassium decreased (13; 1.6), sodium decreased (13; -), lipase increased (12; 4.4), ALT increased (11; 1.6), potassium increased (11; 0.8), alkaline phosphatase increased (11; -). Grade 4 laboratory abnormalities in >5% of patients included
More news about: Eli Lilly and Company
Jun 25, 2026, 07:00 ET Mwyngil Therapeutics Announces Positive in vivo Proof of Concept Data for First-in-Class GPR75 Inverse Agonist in Obesity and Cardiometabolic Disease.
HbA1cReductions of systemic inflammatory markers, including CRP and IL-18Reduced liver weight and improvement of hepatic and lipid biomarkers including ALT/AST and LDL/total cholesterol
More news about: Mwyngil Therapeutics
Jun 23, 2026, 12:00 ET Children's Hospital of Philadelphia Announces CEO Transition, Marking New Chapter in Its 170+ Year Legacy
. Contact: Dan AltChildren's Hospital of [email protected]
More news about: Children's Hospital of Philadelphia
Jun 23, 2026, 10:31 ET Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight
11.2ANKTIVA (N-803/ALT-803): ImmunityBio11.2.1
More news about: DelveInsight Business Research, LLP
Jun 18, 2026, 20:56 ET A Field of Their Own: UAE Embassy, Children's Hospital of Philadelphia and Philadelphia Parks & Recreation Bring the Spirit of Soccer to Conestoga Park in West Philadelphia
www.phila.gov/parksandrec, and follow @philaparkandrec on Facebook, Twitter, and Instagram.Contact: Dan AltChildren's Hospital of Philadelphia(631) [email protected]
More news about: Children's Hospital of Philadelphia
Jun 17, 2026, 07:00 ET UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)
Transaminases Elevated liver transaminase [alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)] levels were reported in patients treated with KYGEVVI. Obtain baseline liver transaminase (ALT, AST) and total bilirubin levels in patients prior to treatment initiation with
More news about: UCB
Jun 16, 2026, 16:01 ET Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
abnormalities, were decreased white blood cells, increased AST, musculoskeletal pain, fatigue, decreased hemoglobin, decreased neutrophils, increased ALT, increased alkaline phosphatase, nausea, decreased blood potassium, increased bilirubin, decreased appetite, electrocardiogram QT prolonged, decreased
More news about: Rigel Pharmaceuticals, Inc.
Jun 16, 2026, 10:35 ET Der „The Donn" von Craft Irish Whiskey erhält bei der IWSC 2026 98 Punkte und zählt damit zu den weltweit am besten bewerteten Whiskys
hat, und glauben, dass diese Art der Reifung erst einen kleinen Vorgeschmack darauf gibt, was alles möglich ist."Obwohl The Donn erst 6,9 Jahre alt ist, bietet er ein Geschmackserlebnis, das man normalerweise erst bei einem viel älteren Whisky erwartet.Craft Irish Whiskey führt dies eher auf
More news about: Craft Irish Whiskey
Jun 16, 2026, 08:42 ET TruLife Distribution Marks Seven Years of Driving Results for Health and Wellness Brands
Alt Beverage Expo.Helping an award-winning calendula-based skincare brand launch an independent retailer rollout that included over 30
More news about: TruLife Distribution
Jun 16, 2026, 06:57 ET Mehr als nur ein Strand: Hainan hat vieles zu bieten
Dort gibt es ein Hotel mit eigenem künstlichen Wellenbad, in dem es ganz einfach ist, Surfen zu lernen – auch für absolute Anfänger, egal ob jung oder alt!Nach all diesen Erlebnissen kann ich es kaum erwarten, mit meiner Familie wiederzukommen. Meine Kinder würden am liebsten jeden Tag am goldenen
More news about: China Daily
Jun 14, 2026, 03:15 ET Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
AST increased (17; 1.6), pneumonia (16; 14), bruising (16; -), potassium decreased (13; 1.6), sodium decreased (13; -), lipase increased (12; 4.4), ALT increased (11; 1.6), potassium increased (11; 0.8), alkaline phosphatase increased (11; -). Grade 4 laboratory abnormalities in >5% of patients included
More news about: Eli Lilly and Company
Jun 13, 2026, 06:33 ET New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
TALVEY® as recommended based on severity.Hepatotoxicity: TALVEY® can cause hepatotoxicity. Elevated ALT occurred in 33% of patients, with Grade 3 or 4 ALT elevation occurring in 2.7%; elevated AST occurred in 31% of patients, with Grade 3 or 4 AST elevation occurring in 3.3%. Grade
More news about: Johnson & Johnson
Jun 12, 2026, 08:00 ET Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
patients with advanced solid tumors receiving ZEPZELCA as a single agent, Grade 3 elevations of ALT and AST were observed in 6% and 3% of patients, respectively, and Grade 4 elevations of ALT and AST were observed in 0.4% and 0.5% of patients, respectively. The median time to onset of Grade ≥3
More news about: Jazz Pharmaceuticals plc
Jun 10, 2026, 09:00 ET ParentSquare, the Leader in K-12 School-Home Engagement, Named "Family Engagement Platform of the Year"
Contactability Benchmark provides districts with the insights they need to measure and improve their ability to reach every family. Rewrite with AI and AI Alt Text help staff create clearer, more accessible communications, while AI Conversation Starters help families extend learning beyond the classroom."ParentSquare
More news about: ParentSquare
Jun 10, 2026, 05:00 ET Alteogen Showcases ALT-B4's Potential to Transform ADC Development at World ADC Summit 2026
to SC administration without ALT-B4Reduced local toxicity: The ALT-B4 combination SC group showed a notable, dose-dependent reduction in local dermal toxicity at the injection siteImproved hematologic safety: Compared to IV infusion, the ALT-B4 combination SC group exhibited
More news about: Alteogen Inc.
Jun 09, 2026, 11:00 ET From Creator Seeding to Retail Velocity in 18 Months: 5W Releases the CPG Creator Seeding Playbook 2026
baby and parent, home and housewares, alcohol, and emerging categories including functional beverage, GLP-1-aligned nutrition, and alt-protein. The Playbook includes deal-by-deal economics for each tier and the buyer-by-buyer briefing protocol for the top ten U.S. retailers.The full
More news about: 5W Public Relations
Jun 08, 2026, 08:31 ET MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential
reduction versus control (p<0.05), with endpoint fat mass and epididymal fat weight reduced by 43.5% and 42.1%, respectively. All treatments decreased ALT, with the largest reduction rate of 83.5% in the combination group. Histopathologic assessment showed significant improvements in hepatic lipid accumulation,
More news about: MetaVia Inc.
Jun 08, 2026, 03:00 ET UGREEN lancerer NASync DXP GT med fokus på hastighed, ydeevne og pålidelighed
udgivne Surveillance Center-app udvider disse muligheder yderligere ved at understøtte de gængse protokoller og tilbyde en samlet løsning, der dækker alt fra kameraadgang og lagring til livevisning, afspilning og systemadministration.Opbevaringsfleksibilitet er en anden af de nye produktseriens
More news about: UGREEN Limited